Sensitization by chronic diazepam treatment of A(2A) adenosine receptor- mediated relaxation in rat pulmonary artery

Life Sciences

Volumn 64, Issue 2, 1998, Pages 19-25

  Ujfalusi, Anikó ^a   Cseppento, Ágnes ^a   Nagy, Erzsébet ^a   Szabó, Judit Zs ^a   Kovács, Péter ^a   Szentmiklósi, A József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Adenosine receptor; Diazepam; Dipyridamole; Myocardium; NBTI; Pulmonary artery

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 N CYCLOPENTYLADENOSINE; ACETYLCHOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; DIAZEPAM; DIPYRIDAMOLE; NITROBENZYLTHIOINOSINE; NORADRENALIN BITARTRATE; RECEPTOR SUBTYPE; SODIUM CHLORIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HEART ATRIUM MUSCLE; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM CARE; MEMBRANE TRANSPORT; NONHUMAN; PULMONARY ARTERY; RAT; RECEPTOR SENSITIVITY; VASODILATATION;

ADENOSINE; ANIMALS; CARRIER PROTEINS; DIAZEPAM; DINUCLEOSIDE PHOSPHATES; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; HEART ATRIA; MUSCLE RELAXATION; PHENETHYLAMINES; PULMONARY ARTERY; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; THIOINOSINE; TRIAZINES; TRIAZOLES; VERAPAMIL;

ANIMALIA;

EID: 0032484271     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. 1. M. HAWKINS, M. PRAVICA and M. RADULOVACKI, Pharmacol. Biochem. Behav. 30 303-308 (1988)
2. 2. M. HAWKINS, P. HAJDUK, S. O'CONNOR, M. RADULOVACKI and K.E. STARZ, Brain Res. 505 141-144 (1989)
3. 3. G.B. KAPLAN, M.M. COTREAU, D.J. GREENBLATT, J. Pharm. Pharmacol. 44 700-703 (1992)
4. 4. R.M. BERNE, Physiol. Rev. 44 1-29 (1964)
5. 5. R.A. OLSSON and J.D. PEARSON, Physiological Rev. 70 761-845 (1990)
6. 6. J.W. PHILLIS, A.S. BENDER, and P.H. WU, Brain Res. 195 494-498 (1980)
7. 7. A. S. CLANACHAN and R.J. MARSHALL, Br. J. Pharmacol. 71 459-66 (1980)
8. 8. T.P. KENAKIN, J. Pharmacol. Exp. Ther. 222 752-758 (1982)
9. 9. D.M. DENNIS, J.C. SHRYOCK and L. BELARDINELLI, J. Pharmacol. Exp. Ther. 272 1024-1035 (1995)
10. 10. H.T. LEE, C.I. THOMPSON, J. LINDEN and F. BELLONI, Am. J. Physiol. 264 H1634-HI643 (1993)
11. 11. A.J. SZENTMIKLÓSI, Á. CSEPPENTO, A. UJFALUSI, J.Zs. SZABÓ, P. KOVÁCS and R.A. OLSSON, Naunyn-Schmiedeberg's Arch. Pharmacol. 356 Suppl 1 R7 (1997)
12. 12. S.V. HOPKINS and R.G. GOLDIE, Biochem. Pharmacol. 20 3359-3365 (1971)
13. 13. J.R. HAMMOND and A.S. CLANACHAN, J. Neurochem. 45 527-535 (1985)
14. 14. R.L. WEBB, M.A. SILLS, J.P. CHOVAN, J.V. PEPPARD and J.E. FRANCIS, J. Pharmacol. Exp. Ther. 267 287-295 (1993)
15. 15. C. CASATI, A. MONOPOLI, S DIONISOTTI, C. ZOCCHI, E. BONIZZONI and E. ONGINI, J. Pharmacol. Exp. Ther. 268 1506-11 (1994)
16. 16. T. HUSSAIN, J.H. LEIGH and S.J. MUSTAFA, J. Cardiovasc. Res. 24 95-99 (1994)
17. 17. H. Van BELLE, K.R. DONCK and W. VERHEYEN, Cardiovasc. Res. 27 111-115 (1993)
18. 18. G. LOZZA, A. CONTI, E. ONGINI and A. MONOPOLI, Pharmacol. Res. 35 57-64 (1997)